The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Drug shows promise for treating both COVID-19 and cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center have published studies focused on GRP78, a protein implicated in both COVID-19 and multiple types of cancer, and a drug that interferes with its effects.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

UPMC “weighted” lottery program improved equity in allocation of scarce medication

A “weighted” lottery program designed to ensure that people living in the most disadvantaged U.S. neighborhoods would be offered a scarce, potentially life-saving medication proved feasible in a large health system. The approach can improve equity in receipt of the drug by people disproportionately affected by disease, according to an analysis published today in JAMA Health Forum by University of Pittsburgh and UPMC scientist-clinicians.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account